☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
approval
Insights+: The US FDA New Drug Approvals in October 2022
November 17, 2022
Samsung Bioepis’s Ontruzant (biosimilar, trastuzumab) Receives the Health Canada Approval for the Treatment of Breast & Gastric Ca...
February 2, 2022
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma
November 19, 2021
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma
November 19, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as an Adjuvant Therapy for Renal Cell Carcinoma
November 19, 2021
Antengene's Selinexor (ATG-010) Receives NMPA's IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma
November 19, 2021
Load more...
Back to Home